Histalim
2005
FOUNDED
M&A
STATUS
31-40
EMPLOYEES
Buyout/LBO
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Provider of histology, immunohistochemistry (IHC), In Situ Hybridization (ISH) and image analysis services. The company is engaged in development of new therapies in the domains of oncology and chronic diseases, including therapeutic antibody and new generation diagnostic tools. It also takes part in development projects for pharmaceutic products, medical devices and diagnostic tools.
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Primary Office
- 126 Rue Emile Baudot
- 34000 Montpellier
- France
+33 04 00 00 00 00
Histalim Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Histalim‘s full profile, request access.
Request full access to PitchBookHistalim Competitors (3)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Empire Genomics | Venture Capital-Backed | Buffalo, NY | 00.000 | 0000000000 0 | 00.000 | |
| 00000000 0000 | Corporation | Boulder, CO | ||||
| 0000000 0000 00000 | Corporate Backed or Acquired | Maryland Heights, MO | 000000&0 |